Loading…
Employees: 4,553
Size Evotec (EVT.DE) is a Germany Health Care company (Miscellaneous Commercial Services) with a market value of $630M, the 169th largest of 205 Germany companies the cockpit tracks. Shares closed at €3.16 on 6 Nov 2026.
Performance Over six months the shares fell 32.7%, against +19.2% for the median peer and +2.6% for the Germany market (cap-weighted) — 2nd lowest of 9 in its peer set.
Growth Revenue fell 7.7% over the last twelve months (peer median -4.5%); the operating margin is -18.6% (peer median -58.4%).
Valuation It trades at 0.8× enterprise value to sales against a peer median of 9.7× (2nd cheapest of 7).
Capital Return on invested capital runs 21.3 points below its cost of capital (7.5% WACC).
Credit Evotec has 1 bond outstanding ($129M).
Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €717M | €788M | €797M | €781M | €751M |
| Revenue growth | — | -1% | +2% | +4% | — |
| Gross profit | €75.3M | €65.2M | €65.9M | €175M | €174M |
| EBITDA | -€36.0M | -€41.4M | -€69.4M | -€7.16M | €13.0M |
| Net income | -€197M | -€104M | -€196M | -€83.9M | -€176M |
| Free cash flow | -€161M | -€82.0M | -€99.5M | -€179M | €21.8M |
| Capital expenditure | €58.7M | €82.6M | €132M | €216M | €181M |
| Total debt | €476M | €448M | €439M | €626M | €507M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EVT.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.8% | -4.1% | 3rd highest of 9 |
| 6-month return | -32.7% | +19.2% | 2nd lowest of 9 |
| Distance from 52-week high | -53.0% | -23.7% | 2nd lowest of 9 |
| Revenue growth (TTM) | -7.7% | -4.5% | 2nd lowest of 6 |
| Operating margin | -18.6% | -58.4% | 4th highest of 7 |
| EV / Sales | 0.8× | 9.7× | 2nd cheapest of 7 |
| ROIC minus cost of capital | -21.3 pp | -8.7 pp | 2nd lowest of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Evotec EVT.DE | Germany | $630M | -33% | -8% | -19% | 0.8× | n/a | n/a |
| Adlai Nortye Ltd. Sponsored ADR ANL | United States | $619M | -23% | n/a | -134% | 22.8× | n/a | n/a |
| OmniAb OABI | United States | $734M | +29% | +91% | -116% | 17.1× | 59.6% | -31.9% |
| SBC Medical SBC | United States | $518M | +58% | -7% | 37% | 2.3× | -16.1% | -6.9% |
| Evolent Health EVH | United States | $518M | +10% | -4% | -1% | 0.6× | 22.6% | +15.2% |
| Oculis OCS | United States | $462M | -77% | n/a | n/a | n/a | n/a | n/a |
| Tectonic Therapeutic TECX | United States | $403M | -29% | n/a | n/a | n/a | n/a | n/a |
| Silence Therapeutics PLC Sponsored ADR SLN | United States | $1.23B | +184% | -97% | -10,478% | 1,889.5× | n/a | n/a |
| Fortrea FTRE | United States | $2.12B | +42% | -3% | 2% | 1.1× | 32.9% | +1.1% |
Evotec has 1 bond outstanding with $129M face value.